In contrast, angiogenesis and epithelial–mesenchymal transition (EMT) pathways were upregulated (Figure 3b), suggesting a potential benefit from targeting the VEGF pathway in breast cancer patients with FH aberrations. This evidence concerns the gene VEGFA and breast carcinoma.